Sava reports world-first 10-day clinical evidence for continuous glucose monitoring via proprietary microsensor technology

Full cohort results show glucose can be accessed and measured in interstitial fluid using Sava’s proprietary microsensor technology over a 10-day period Milestone validates the clinical foundation for Sava’s pioneering biosensing platform, which performs comparably to filament-based CGMs Sava targeting 2027 for commercial availability, subject to regulatory approval London, 08:00am, 10th February 2026: Sava Technologies, the London-based startup pioneering real-time molecular health…